Logo image of RXST

RXSIGHT INC (RXST) Stock Fundamental Analysis

NASDAQ:RXST - Nasdaq - US78349D1072 - Common Stock - Currency: USD

8  -0.46 (-5.44%)

After market: 8.199 +0.2 (+2.49%)

Fundamental Rating

4

Taking everything into account, RXST scores 4 out of 10 in our fundamental rating. RXST was compared to 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of RXST is average, but there are quite some concerns on its profitability. RXST is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RXST had negative earnings in the past year.
RXST had a negative operating cash flow in the past year.
In the past 5 years RXST reported 4 times negative net income.
In the past 5 years RXST always reported negative operating cash flow.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.48%, RXST is in the better half of the industry, outperforming 64.17% of the companies in the same industry.
Looking at the Return On Equity, with a value of -9.50%, RXST is in the better half of the industry, outperforming 66.84% of the companies in the same industry.
Industry RankSector Rank
ROA -8.48%
ROE -9.5%
ROIC N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

The Gross Margin of RXST (71.87%) is better than 83.42% of its industry peers.
RXST's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for RXST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

6

2. Health

2.1 Basic Checks

RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RXST has more shares outstanding
Compared to 5 years ago, RXST has more shares outstanding
The debt/assets ratio for RXST has been reduced compared to a year ago.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

RXST has an Altman-Z score of 4.07. This indicates that RXST is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of RXST (4.07) is better than 74.87% of its industry peers.
RXST has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
RXST has a better Debt to Equity ratio (0.00) than 71.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.07
ROIC/WACCN/A
WACC9.07%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

RXST has a Current Ratio of 12.68. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
RXST has a Current ratio of 12.68. This is amongst the best in the industry. RXST outperforms 94.65% of its industry peers.
RXST has a Quick Ratio of 11.65. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RXST (11.65) is better than 94.65% of its industry peers.
Industry RankSector Rank
Current Ratio 12.68
Quick Ratio 11.65
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.63% over the past year.
Looking at the last year, RXST shows a very strong growth in Revenue. The Revenue has grown by 46.69%.
The Revenue has been growing by 128.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)44.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)46.69%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%28.41%

3.2 Future

RXST is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.26% yearly.
The Revenue is expected to grow by 14.08% on average over the next years. This is quite good.
EPS Next Y-25.83%
EPS Next 2Y-7.03%
EPS Next 3Y5.26%
EPS Next 5YN/A
Revenue Next Year15.06%
Revenue Next 2Y13.74%
Revenue Next 3Y15.39%
Revenue Next 5Y14.08%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RXST. In the last year negative earnings were reported.
Also next year RXST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.03%
EPS Next 3Y5.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RXST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RXSIGHT INC

NASDAQ:RXST (7/11/2025, 8:00:02 PM)

After market: 8.199 +0.2 (+2.49%)

8

-0.46 (-5.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners93.64%
Inst Owner Change0%
Ins Owners5.51%
Ins Owner Change8.6%
Market Cap325.12M
Analysts76.47
Price Target22.03 (175.38%)
Short Float %12.93%
Short Ratio5.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.14%
Min EPS beat(2)9.22%
Max EPS beat(2)11.05%
EPS beat(4)4
Avg EPS beat(4)21.58%
Min EPS beat(4)9.22%
Max EPS beat(4)36.3%
EPS beat(8)8
Avg EPS beat(8)21.55%
EPS beat(12)12
Avg EPS beat(12)20.96%
EPS beat(16)15
Avg EPS beat(16)18.28%
Revenue beat(2)0
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)-2.21%
Revenue beat(4)1
Avg Revenue beat(4)-0.01%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)5.95%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)3.54%
Revenue beat(16)12
Avg Revenue beat(16)4.82%
PT rev (1m)0%
PT rev (3m)-48.71%
EPS NQ rev (1m)-19.94%
EPS NQ rev (3m)-28.49%
EPS NY rev (1m)-33.68%
EPS NY rev (3m)-66.54%
Revenue NQ rev (1m)-3.08%
Revenue NQ rev (3m)-7.98%
Revenue NY rev (1m)-3.88%
Revenue NY rev (3m)-5.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.19
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS3.65
BVpS6.87
TBVpS6.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.48%
ROE -9.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.87%
FCFM N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
F-Score5
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 123.83%
Cap/Sales 2.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.68
Quick Ratio 11.65
Altman-Z 4.07
F-Score5
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)107.67%
Cap/Depr(5y)87%
Cap/Sales(3y)4.72%
Cap/Sales(5y)8.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-25.83%
EPS Next 2Y-7.03%
EPS Next 3Y5.26%
EPS Next 5YN/A
Revenue 1Y (TTM)46.69%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%28.41%
Revenue Next Year15.06%
Revenue Next 2Y13.74%
Revenue Next 3Y15.39%
Revenue Next 5Y14.08%
EBIT growth 1Y22.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.49%
EBIT Next 3Y27.87%
EBIT Next 5YN/A
FCF growth 1Y68.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.27%
OCF growth 3YN/A
OCF growth 5YN/A